Document is current
Any future updates will be listed below
-
Authors
Huebschmann, Amy G. http://orcid.org/0000-0002-9329-3142
Wagner, Nicole M.
Gleason, Melanie
Brinton, John T.
Brtnikova, Michaela
Brewer, Sarah E.
Begum, Anowara
Armstrong, Rachel
DeCamp, Lisa Ross
McFarlane, Arthur
DeKeyser, Heather
Coleman, Holly
Federico, Monica J.
Szefler, Stanley J.
Cicutto, Lisa C.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (K01DA056698)
National Heart, Lung, and Blood Institute (UG3HL151297, UH3HL151297, K23HL146791)
Colorado Department of Public Health and Environment (Expansion 2024*0346)
- License Information
-
More Information
Article History
Received: 21 June 2024
Accepted: 16 July 2024
First Online: 15 August 2024
Declarations
:
: The proposed research was reviewed by the Colorado Multiple Institutional Review Board (COMIRB), approval number 20–0883; the amendment to approve the protocol for this type 2 hybrid effectiveness-implementation trial was approved on 10/19/2023.
: Not applicable.
: - AGH, NMW, MG, JTB, MB, SEB, AB, RA, LRD, AMF, HDK, HC, MF and LCC declare that they have no competing interests.- Declaration of potential competing interests for SJS: prior service as a consultant for new drug development for Astra Zeneca, Eli Lilly, GlaxoSmithKline, Moderna, OM Pharma, Propeller Health, Regeneron, and Sanofi. This proposal does not involve comparisons of asthma medications.
